25-G Vitrectomy With Ranibizumab or Triamcinolone Acetonide on PDR in China-Randomized Clinical Trial
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
Proliferative diabetic retinopathy(PDR) is the leading cause of visual loss in diabetic
patients. Operation is an efficient method to treat PDR. Anti-vascular endothelial growth
factor (anti-VEGF) can be used as an adjuvant therapy which can make operation more easy.